My patient has a test-proven Candida allergy. Because hepatitis B virus (HBV)vaccine contains yeast, another physician would not give it to him. I administereda diluted dose and then a full-strength dose of the HBV vaccine, and the patienthad no adverse reaction.
My patient has a test-proven Candida allergy. Because hepatitis B virus (HBV)vaccine contains yeast, another physician would not give it to him. I administereda diluted dose and then a full-strength dose of the HBV vaccine, and the patienthad no adverse reaction.What explains the absence of a reaction in this patient? In general, what precautionsshould be taken when HBV vaccine is given to persons with a documentedyeast allergy?-- William Morris, MD
 Athens, TennThe term "yeast" is not the most precise one to describe the mediumused in the development of HBV vaccine. Recombinant HBV vaccineis produced in a species of yeast cells, namely Saccharomyces cerevisiae.Most of the yeast components in the vaccine are removed by physicalseparation techniques (eg, chromatography and filtration). Thelack of reaction in your patient with a Candida allergy may be a result of thedifference in species and/or of the separation process.Anaphylaxis resulting from HBV vaccine has been reported in the literature.1 Vaccination is contraindicated in patients who have experienced anaphylaxisin response to the vaccine or to one of its components.-- Richard K. Zimmerman, MD, MPH
  Associate Professor
  Department of Family Medicine and Clinical Epidemiology
  University of Pittsburgh School of Medicine
REFERENCE:
1.
Vaccine Safety Committee, Institute of Medicine. Hepatitis B vaccine. In: Stratton KR, Howe CJ, JohnstonRB, eds.
Adverse Events Associated With Childhood Vaccines.
Washington, DC: National Academy Press; 1994:
228-231.
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
September 30th 2025The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.